Consensus HealthEquity, Inc.

Equities

HQY

US42226A1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
80.26 ^USD	+1.54%		-0.78%	+21.06%

Apr. 04	JMP Securities Initiates Coverage on HealthEquity With Market Outperform Rating, $101 Price Target	MT
Apr. 02	JPMorgan Adjusts Price Target on HealthEquity to $108 From $86, Maintains Overweight Rating	MT

Evolution of the average Target Price on HealthEquity, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6a85aca4f.6N2X3HlZmTXT0fWHoT5ICwEVhjct_3Uaa2j4kwJ8mBU.0ZbUlC0c7n6V4p3qk18FMkVUwwFb0j91DxLVqlMa0Fuki6KeOzfqcOHosA~6047dc7ef3e0b987121b4766c8992a8b

Analyst Recommendations on HealthEquity, Inc.

JMP Securities Initiates Coverage on HealthEquity With Market Outperform Rating, $101 Price Target	Apr. 04	MT
JPMorgan Adjusts Price Target on HealthEquity to $108 From $86, Maintains Overweight Rating	Apr. 02	MT
Jefferies Adjusts HealthEquity Price Target to $95 From $79, Maintains Buy Rating	Mar. 28	MT
BTIG Research Adjusts HealthEquity Price Target to $110 From $100, Maintains Buy Rating	Mar. 20	MT
RBC Raises Price Target on HealthEquity to $92 From $90, Notes Fiscal Q4 Results at High End of Preannounced Ranges; Outperform Kept	Mar. 20	MT
Barrington Raises PT on HealthEquity to $100 From $85, Expects Improving Operating and Financial Performance, Keeps Outperform Rating	Feb. 26	MT
Barclays Adjusts HealthEquity's Price Target to $104 From $84, Keeps Overweight Rating	Feb. 23	MT
Deutsche Bank Adjusts HealthEquity Price Target to $95 From $88, Maintains Buy Rating	Feb. 23	MT
RBC Raises Price Target on HealthEquity to $90 From $77, Keeps Outperform Rating	Feb. 23	MT
Deutsche Bank Raises HealthEquity Price Target to $88 From $85, Maintains Buy Rating	Dec. 07	MT
Wells Fargo Adjusts HealthEquity's Price Target to $93 From $89, Maintains Overweight Rating	Dec. 06	MT
Deutsche Bank Raises HealthEquity's Price Target to $85 From $72, Maintains Buy Rating	23-10-26	MT
Baird Upgrades HealthEquity to Outperform From Neutral, Raises Price Target to $87 From $79	23-09-21	MT
Deutsche Bank Adjusts HealthEquity Price Target to $72 From $71, Maintains Buy Rating	23-09-07	MT
RBC Lifts PT on HealthEquity to $77 From $75 After Fiscal Q2 Beat, Fiscal 2024 Guidance, Keeps Outperform Rating	23-09-06	MT
Baird Adjusts Price Target on HealthEquity to $79 From $77, Maintains Neutral Rating	23-09-06	MT
Barrington Raises PT on HealthEquity to $85 From $80 After Fiscal Q2 Results Surpass Expectations, Maintains Outperform Rating	23-09-06	MT
RBC Lifts Price Target on HealthEquity to $77 From $75 After Fiscal Q2 Beat, Fiscal 2024 Guidance Boost, Keeps Outperform Rating	23-09-06	MT
JPMorgan Cuts HealthEquity's Price Target to $81 From $84, Maintains Overweight Rating	23-06-20	MT
Deutsche Bank Adjusts HealthEquity Price Target to $71 From $69, Maintains Buy Rating	23-06-07	MT
Deutsche Bank Adjusts HealthEquity Price Target to $69 From $72, Maintains Buy Rating	23-03-24	MT
Wells Fargo Adjusts Price Target on HealthEquity to $89 From $101, Maintains Overweight Rating	23-02-03	MT
Deutsche Bank Adjusts HealthEquity's Price Target to $72 From $68, Maintains Buy Rating	23-01-24	MT
Raymond James Adjusts HealthEquity Price Target to $85 From $75, Maintains Outperform Rating	22-12-12	MT
Wells Fargo Adjusts Price Target on HealthEquity to $101 From $104, Maintains Overweight Rating	22-12-07	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

80.26 USD

Average target price

98.01 USD

Spread / Average Target

+22.12%

High Price Target

110 USD

Spread / Highest target

+37.05%

Low Price Target

84.2 USD

Spread / Lowest Target

+4.91%

Consensus detail

Consensus revision (last 18 months)

Analysts covering HealthEquity, Inc.

JMP Securities
JPMorgan Chase
Jefferies & Co.
BTIG
RBC Capital Markets
Barrington Research
Barclays
Deutsche Bank Securities
Wells Fargo Securities
Baird
Raymond James
Guggenheim
Goldman Sachs
KeyBanc Capital Markets
SVB Securities LLC
BofA Securities
Stephens Inc.
SVB Leerink
Cantor Fitzgerald

Ratings for HealthEquity, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar